[Does simultaneous administration of a PGE1 analog prevent indomethacin damage to human gastric mucosa? An endoscopic double-blind study].
The influence on gastroduodenal mucosa of indomethacin (50 mg t.i.d.) administration for 6 days was investigated in 7 healthy volunteers in a double-blind randomized crossover study with and without concomitant administration of MDL 646, 400 micrograms q.i.d. and 800 micrograms q.i.d. Indomethacin induced a gastroduodenal lesion index of 2.4 +/- 0.1. Neither of the prostaglandin E1-analogue dosages afforded significant protection of gastric and duodenal mucosa (2.1 +/- 0.4 in the presence of 400 micrograms q.i.d. and 1.9 +/- 0.4 in the presence of 800 micrograms q.i.d.). Major side effects were not observed.
D000328:Adult; D000527:Alprostadil / Q000031:analogs & derivatives* / Q000494:pharmacology; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005753:Gastric Mucosa / Q000187:drug effects*; D005773:Gastroscopy; D006801:Humans; D007213:Indomethacin / Q000633:toxicity*; D008297:Male; D011459:Prostaglandins E, Synthetic; D011897:Random Allocation
D000897:Anti-Ulcer Agents; D011459:Prostaglandins E, Synthetic; D000527:Alprostadil; C036058:mexiprostil; D007213:Indomethacin
Verhindert die gleichzeitige Gabe eines PGE1-Analogs Indometacinschäden an der menschlichen Magenschleimhaut? Eine endoskopische Doppelblind-Studie.